The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
NUFYMCO BLA has been approved by the USFDA
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Subscribe To Our Newsletter & Stay Updated
